Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Sodium chloride 0.9% is an isotonic solution that expands extracellular fluid volume, replacing sodium and chloride deficits. Sodium is the primary cation maintaining osmotic pressure and acid-base balance; chloride is the major extracellular anion. The solution provides electrolyte replacement and hydration without altering serum osmolality.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous, 100-200 mL/hour for maintenance; up to 1000 mL bolus for volume resuscitation in adults.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable; sodium and chloride ions are endogenous substances with no defined terminal elimination half-life. Excretion half-life is dependent on renal function, typically 6-12 hours in individuals with normal kidney function.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >95% of administered sodium and chloride ions are excreted unchanged in urine; fecal and biliary elimination are negligible (<1%).
Category C
Category A/B
Electrolyte
Electrolyte